CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Pulike Biological Engineering Inc Company Snapshot
Pulike Biological Engineering Inc operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Pulike Biological Engineering Inc with three other companies in this sector in CHINA : Zhejiang Wolwo Bio Pharmaceutical Co Ltd (2019 sales of 639.35 million Chinese Renmimbi [US$94.41 million] of which 99% was Pharmaceutical Manufacturing), Shenzhen Weiguang Biological Products Co Ltd (821.47 million Chinese Renmimbi [US$121.31 million] of which 99% was Blood Products), and Staidson (Beijing) Biopharmaceuticals Co Ltd (661.49 million Chinese Renmimbi [US$97.68 million] of which 100% was Pharmaceutical manufacturing).

Sales Analysis. Pulike Biological Engineering Inc reported sales of 663.15 million Chinese Renmimbi (US$97.93 million) for the year ending December of 2019. This represents an increase of 9.1% versus 2018, when the company's sales were 608.06 million Chinese Renmimbi. Sales of Other Operation saw an increase that was more than double the company's growth rate: sales were up 31.4% in 2019, from 8.12 million Chinese Renmimbi to 10.66 million Chinese Renmimbi. Not all segments of Pulike Biological Engineering Inc experienced an increase in sales in 2019: sales of Technology License and Transfer Income fell 21.8% to 23.54 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales).
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Pulike Biological Engineering Inc
  Stock Performance Chart for Pulike Biological Engineering Inc
 
  Stock Data: Recent Stock Performance:
  Current Price (9/18/2020): 24.86
(Figures in Chinese Renmimbi)
1 Week 0.5%   13 Weeks -7.8%  
4 Weeks -13.1%   52 Weeks 18.1%  
 
Pulike Biological Engineering Inc Key Data:
  Ticker: 603566 Country: China
  Exchanges: SHG Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2019 Sales 663,154,440
(Year Ending Jan 2020).
Employees: 1,509
  Currency: Chinese Renmimbi Market Cap: 7,992,390,560
  Fiscal Yr Ends: December Shares Outstanding: 321,496,000
  Share Type: GU Closely Held Shares:
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.